|
Volumn 353, Issue 26, 2005, Pages 2739-2741
|
Benefits and consequences for the poor and the disabled
a b c c |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
ANTIDIABETIC AGENT;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
BENZODIAZEPINE;
GENERIC DRUG;
IMMUNOSUPPRESSIVE AGENT;
NEUROLEPTIC AGENT;
OPIATE;
THIAZIDE DIURETIC AGENT;
DISABILITY;
DRUG COST;
DRUG FORMULARY;
DRUG SAFETY;
HEALTH CARE ACCESS;
HEALTH CARE DELIVERY;
HEALTH CARE POLICY;
HEALTH HAZARD;
HEALTH PROGRAM;
HUMAN;
LOWEST INCOME GROUP;
MEDICAID;
MEDICARE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
UNSPECIFIED SIDE EFFECT;
DEDUCTIBLES AND COINSURANCE;
DISABLED PERSONS;
ELIGIBILITY DETERMINATION;
FORMULARIES;
HUMANS;
INSURANCE COVERAGE;
INSURANCE, PHARMACEUTICAL SERVICES;
MEDICAID;
MEDICARE;
POVERTY;
PRESCRIPTION FEES;
UNITED STATES;
|
EID: 29544440939
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp058242 Document Type: Short Survey |
Times cited : (24)
|
References (5)
|